Systemic Inflammation after Transcatheter Aortic Valve Implantation: A Prospective Exploratory Study

Rettig, Thijs C D; Nijenhuis, Vincent J.; Meek, Bob; Rigter, Sander; Berg, Jürrien M. ten; Vlaminckx, Bart J. M.; Klei, Wilton A. van; Garde, E.M.W. van de; Peelen, Linda M.; Noordzij, Peter G.

doi:10.1053/j.jvca.2017.12.051

Cited by 3 publications

(2 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The occurrence of a systemic inflammatory response after TAVR has been the focus of investigation in only a few studies and it has been associated with inferior outcomes [4,5,15]. Sinning et al [4] and Lindman et al [5], who used a transfemoral approach for TAVR, as was applied in this study, reported an incidence of 40% and 63%, respectively.…”

Section: Discussionmentioning

confidence: 76%

Evaluation of systemic inflammation in response to remote ischemic preconditioning in patients undergoing transcatheter aortic valve replacement (TAVR)

Zhang¹,

Troeger²,

Kühn³

et al. 2022

Rev. Cardiovasc. Med.

View full text Add to dashboard Cite

Background: Systemic inflammation can occur after transcatheter aortic valve replacement (TAVR) and correlates with adverse outcome. The impact of remote ischemic preconditioning (RIPC) on TAVR associated systemic inflammation is unknown and was focus of this study. Methods: We performed a prospective controlled trial at a single center and included 66 patients treated with remote ischemic preconditioning (RIPC) prior to TAVR, who were matched to a control group by propensity score. RIPC was applied to the upper extremity using a conventional tourniquet. Definition of systemic inflammation was based on leucocyte count, C-reactive protein (CRP), procalcitonin (PCT) and interleukin-6 (IL-6), assessed in the first 5 days following the TAVR procedure. Mortality was determined within 6 months after TAVR. RIPC group and matched control group showed comparable baseline characteristics. Results: Systemic inflammation occurred in 66% of all patients after TAVR. Overall, survival after 6 months was significantly reduced in patients with systemic inflammation. RIPC, in comparison to control, did not significantly alter the plasma levels of leucocyte count, CRP, PCT or IL-6 within the first 5 days after TAVR. Furthermore, inflammation associated survival after 6 months was not improved by RIPC. Of all peri-interventional variables assessed, only the amount of the applied contrast agent was connected to the occurrence of systemic inflammation. Conclusions: Systemic inflammation frequently occurs after TAVR and leads to increased mortality after 6 months. RIPC neither reduces the incidence of systemic inflammation nor improves inflammation associated patient survival within 6 months.

show abstract

Section: Discussionmentioning

confidence: 76%

Evaluation of systemic inflammation in response to remote ischemic preconditioning in patients undergoing transcatheter aortic valve replacement (TAVR)

Zhang¹,

Troeger²,

Kühn³

et al. 2022

Rev. Cardiovasc. Med.

View full text Add to dashboard Cite

show abstract

“…Factors such as C-reactive protein and specific gene mutations have been seen in the presence of AF and as a predictor of developing future AF [8]. This inflammatory response may be a possible explanation for the increased incidence of AF in surgical aortic valve replacement (SAVR) and non-femoral TAVI patients [9]. Findings from the SOURCE XT Trial suggest that the presence of either pre-existing or new-onset atrial fibrillation (NOAF) increased all-cause and cardiac mortality [10].…”

Section: Introductionmentioning

confidence: 99%

A Review of the Incidence and Management of New-Onset Atrial Fibrillation Post Transcatheter Aortic Valve Implantation

Saxena¹

2020

AJBSR

View full text Add to dashboard Cite

Transcatheter Aortic Valve Implantation (TAVI) is an established treatment option for patients with aortic stenosis who are considered highrisk for surgical valve replacement. New-onset atrial fibrillation (NOAF) is a serious adverse event post TAVI that is predictive of poor outcomes and whose pathophysiology remains unclear. The incidence of NOAF post-TAVI has a reportedly broad range depending on the study but has been correlated to procedure approach, choice of valve, and the use of general anesthesia. While surgical aortic valve replacement (SAVR) has traditionally been the preferred treatment for aortic stenosis, recent studies have demonstrated the benefits of expanding TAVI into a larger patient population. Additionally, the management of NOAF post-TAVI remains highly variable. This review paper aims to summarize the incidence of NOAF and to outline management strategies.The risk factors for NOAF post-TAVI is an ongoing area of research with many questions remaining to be answered. With the expansion of TAVI into lower-risk patient populations, it is imperative that risk factors for NOAF be determined in order to decrease the likelihood of stroke and mortality after the procedure. Data is still limited on standardized treatment for NOAF, but multiple international drug trials are aiming to discern the optimal anti-platelet and anti-coagulation treatment to improve post-procedure outcomes.

show abstract

Analyse von Risikofaktoren für das Syndrom der systemischen Entzündungsreaktion bei Patienten nach Transkatheter-Aortenklappenersatz

Cheng

Dong²,

Wen³

et al. 2023

Herz

View full text Add to dashboard Cite

Systemic Inflammation after Transcatheter Aortic Valve Implantation: A Prospective Exploratory Study

Cited by 3 publications

References 7 publications

Evaluation of systemic inflammation in response to remote ischemic preconditioning in patients undergoing transcatheter aortic valve replacement (TAVR)

Evaluation of systemic inflammation in response to remote ischemic preconditioning in patients undergoing transcatheter aortic valve replacement (TAVR)

A Review of the Incidence and Management of New-Onset Atrial Fibrillation Post Transcatheter Aortic Valve Implantation

Analyse von Risikofaktoren für das Syndrom der systemischen Entzündungsreaktion bei Patienten nach Transkatheter-Aortenklappenersatz

Contact Info

Product

Resources

About